In this study, we highlighted that a subset of patients treated with first-line anti-HER2 therapy achieved prolonged disease control beyond three years, with a median PFS exceeding 10 years in patients with metastatic HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.